Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

Bruton ’s tyrosine kinase (BTK) is a key signaling node in B cell receptor (BCR) and Fc receptor (FcR) signaling. BTK inhibitors (BTKi) are an emerging oral treatment option for patients suffering from multiple...

Source: Journal of Neuroinflammation - August 26, 2023 Category: Neurology Authors: Barbara Nuesslein-Hildesheim, Enrico Ferrero, Cindy Schmid, Catherine Huck, Paul Smith, Sarah Tisserand, Joelle Rubert, Frederic Bornancin, Denis Eichlisberger and Bruno Cenni Tags: Research Source Type: research